Breaking News

Maravai LifeSciences Acquires DNA and RNA Business of Officinae Bio

The acquisition combines Officinae Bio's AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies' drug substance manufacturing capabilities.

Author Image

By: Charlie Sternberg

Associate Editor

Maravai LifeSciences Inc., a provider of life science reagents and services to researchers and biotech innovators, has completed its previously announced acquisition of Officinae Bio’s DNA and RNA business. This acquisition combines Officinae Bio’s AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies’ drug substance manufacturing capabilities, providing customers comprehensive expertise and novel technologies for quick, calculated progression through the mRNA ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters